<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Mon, 19 Jan 2026 07:20:53 +0000</lastBuildDate>
    <item>
      <title>#1 [82/100] Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41530380/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41530380/</guid>
      <dc:creator>Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 82/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This phase 1 trial evaluates a first-in-class therapy in combination with pembrolizumab for immune checkpoint blockade-resistant tumors, indicating potential for significant clinical benefit and practice-changing implications, especially given its multicenter design and focus on a novel mechanism.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature medicine | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41591-025-04157-w'&gt;10.1038/s41591-025-04157-w&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41530380/'&gt;41530380&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Although immune checkpoint inhibitor therapies have revolutionized oncology, many cancers are unresponsive or develop resistance that involves transforming growth factor-Œ≤1 (TGFŒ≤1). This multicenter, open-label, phase 1 study (DRAGON trial, SRK-181-001) evaluated safety, pharmacokinetics, pharmacodynamics, predictive biomarkers and efficacy of linavonkibart, a first-in-class fully human selective anti-latent TGFŒ≤1 antibody with anti-programmed cell death protein 1 (PD-1) therapy. The DRAGON trial was divided into three treatment parts: part A1 (dose-escalation cohorts with single-agent linavonkibart), part A2 (dose-escalation cohorts with the combination treatment of linavonkibart and pembrolizumab) and part B (dose-expansion cohorts with the combination treatment). The primary objective of the study was to determine the safety and tolerability of linavonkibart alone and in combination with pembrolizumab. Secondary objectives included evaluation of linavonkibart pharmacokinetics for each treatment paradigm, assessment of anti-linavonkibart antibody development (parts A and B) and measurement of antitumor activity (part B) after treatment. All primary and secondary objectives were met in the study. Overall, linavonkibart had a manageable safety profile, and combined therapy with pembrolizumab was generally consistent with that of pembrolizumab monotherapy. Dermatological reactions were the only additional risk identified. Neither cytokine release syndrome nor infusion interruption was observed in any patient enrolled in DRAGON. In part A (n‚Äâ=‚Äâ34), no dose-limiting toxicities or grade 4 or 5 treatment-related adverse events occurred (linavonkibart; ‚â§3,000‚Äâmg once every 3‚Äâweeks (Q3W) and 2,000‚Äâmg once every 2‚Äâweeks (Q2W)). In part B (n‚Äâ=‚Äâ78), patients progressing on prior anti-PD-1 therapy received linavonkibart (1,500‚Äâmg Q3W/1,000‚Äâmg Q2W) with pembrolizumab (200‚Äâmg Q3W). This combination demonstrated confirmed objective response rates of 20.0%, 18.2%, 9.1% and 9.1% in anti-PD-1-resistant patients with clear cell renal cell cancer (ccRCC), melanoma, head and neck squamous cell cancer and urothelial cancer, respectively. Biomarker data provide proof of mechanism and a potential ccRCC patient selection strategy. ClinicalTrials.gov identifier: NCT04291079 .</description>
    </item>
    <item>
      <title>#2 [75/100] Clinical Significance for risk stratification of papillary thyroid cancer by TUMORFISHER circulating tumor cells technique.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41543346/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41543346/</guid>
      <dc:creator>Jiang L, Li X, Ma T, Zeng P, Tan Z, Zheng C, Xu J, Zhang L, Guo Y, Liang J, et al.</dc:creator>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective study with a substantial sample size (n=210) that addresses a significant clinical challenge in risk stratification for papillary thyroid cancer using a novel liquid biopsy technique, which has potential implications for treatment planning.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Jiang L, Li X, Ma T, Zeng P, Tan Z, Zheng C, Xu J, Zhang L, Guo Y, Liang J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-2694'&gt;10.1158/1078-0432.CCR-25-2694&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41543346/'&gt;41543346&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Preoperative risk stratification for papillary thyroid cancer (PTC) is a significant clinical challenge, as current systems primarily rely on postoperative pathology, limiting their utility for initial treatment planning. This study aimed to evaluate the effectiveness of using circulating tumor cells (CTCs) as a non-invasive liquid biopsy tool to stratify patient risk preoperatively. EXPERIMENTAL DESIGN: We conducted a prospective study evaluating preoperative CTC levels in 210 patients diagnosed with PTC. A dual-threshold model was developed to analyze the diagnostic performance of CTC counts. The study particularly focused on the Papillary Thyroid Microcarcinoma (PTMC) subgroup (n=100) to address clinical uncertainty regarding active surveillance versus definitive therapy. Patients were monitored over a median follow-up period of 44 months to assess progression-free survival (PFS) and long-term prognostic outcomes. RESULTS: The dual-threshold model demonstrated excellent diagnostic performance. A cutoff of ‚â• 2 CTCs effectively identified high-risk patients with 93.2% specificity and 88.2% positive predictive value (PPV). In the PTMC cohort, a CTC count &lt; 2 reliably identified low-risk patients suitable for active surveillance (NPV=94.0%), while a count ‚â• 2 pinpointed those with high-risk features warranting surgery (Specificity=96.4%, PPV=80.0%). Prognostic analysis revealed that CTC-negative patients had improved PFS. This was most significant in the PTMC subgroup, where the CTC-negative cohort remained recurrence-free and showed significantly longer PFS compared to CTC-positive cases (HR=0.035, 95% CI: 0.002-0.726; P=0.030). CONCLUSIONS: Preoperative CTC detection enables precise risk stratification for PTC patients. This liquid biopsy approach allows clinicians to personalize therapy-confidently selecting conservative management for low-risk individuals and recommending aggressive treatment for high-risk patients-thereby optimizing clinical decision-making and long-term outcomes.</description>
    </item>
    <item>
      <title>#3 [75/100] Five-year comparison of magnetic resonance imaging and endoscopy for nasopharyngeal carcinoma detection among high-risk populations undergoing screening.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41548058/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41548058/</guid>
      <dc:creator>Zhou HN, Li T, Peng YN, Li H, Wu ZC, Fan YY, King AD, Hildesheim A, Ling W, Liu Z, et al.</dc:creator>
      <pubDate>Thu, 15 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a large prospective study evaluating the effectiveness of MRI versus endoscopy for nasopharyngeal carcinoma detection in a high-risk population, providing important insights that could influence screening practices, although it does not present practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhou HN, Li T, Peng YN, Li H, Wu ZC, Fan YY, King AD, Hildesheim A, Ling W, Liu Z, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/cncr.70256'&gt;10.1002/cncr.70256&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-15&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41548058/'&gt;41548058&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The long-term impact of magnetic resonance imaging (MRI) on nasopharyngeal carcinoma (NPC) detection in screening remains unclear as a result of limited follow-up. METHODS: A prospective population-based screening study was conducted in Southern China from October 2014 to November 2018 among Epstein-Barr virus (EBV)-seropositive individuals aged 30-69 years. EBV-seropositive participants underwent both endoscopy and MRI. Suspicious findings from either modality triggered a second endoscopy with biopsy. Followup for cancer diagnoses was completed via multiple methods in October 2023. Primary end points included the 5-year NPC detection rate (overall and by stage) and the false-negative rate. Secondary end points were sensitivity, specificity, positive predictive value (PPV), and referral rate. RESULTS: The analysis included 814 individuals (455 females; 56%) with a median age of 53 years (interquartile range, 46-60 years). Thirty-two NPC cases were detected (30 via MRI; 21 via endoscopy) over 5 years. MRI showed a significantly higher overall NPC detection rate (36.9 [95% CI, 25.9-52.1] vs. 25.8 [95% CI, 16.9-39.1] per 1000; p¬†=¬†.007) and early-stage tumor detection (20.9 [95% CI, 13.1-27.1] vs. 12.3 [95% CI, 6.7-22.5] per 1000; p¬†=¬†.020) than endoscopy. MRI also demonstrated a lower false-negative rate (3.0 [95% CI, 0.8-11.0] vs. 14.9 [95% CI, 8.4-26.5] per 1000; p¬†=¬†.024) and higher sensitivity (93.8% vs. 65.6%; p¬†=¬†.007) but lower specificity (84.0% vs. 92.8%; p¬†&lt;¬†.001) and PPV (19.6% vs. 27.6%; p¬†=¬†.019). CONCLUSIONS: Single MRI demonstrated superior NPC detection versus endoscopy, particularly for early-stage tumors, in high-risk populations during a 5-year period, which suggests the potential for extending the rescreening interval to 5 years for MRI-negative individuals.</description>
    </item>
    <item>
      <title>#4 [75/100] Smokeless Tobacco and Oral Cancer in Global Perspective.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41534101/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41534101/</guid>
      <dc:creator>Parascandola M, Nethan ST, Siddiqi K</dc:creator>
      <pubDate>Thu, 15 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper addresses an important public health issue regarding smokeless tobacco and its link to oral cancer, published in a top-tier journal, which suggests significant clinical implications and potential to influence guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Parascandola M, Nethan ST, Siddiqi K&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The New England journal of medicine | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1056/NEJMp2500631'&gt;10.1056/NEJMp2500631&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-15&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41534101/'&gt;41534101&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#5 [75/100] Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41535264/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41535264/</guid>
      <dc:creator>Zhou Y, Wang Y, Shi X, Wang J, Zang Z, Zhang L, Gui Z, Cai X, Hu P, Wang J, et al.</dc:creator>
      <pubDate>Wed, 14 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large multi-center analysis of 482 medullary thyroid carcinoma samples, providing important insights into recurrence risk factors and molecular subtypes, which could influence clinical practice, though it does not present a randomized controlled trial or definitive practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Zhou Y, Wang Y, Shi X, Wang J, Zang Z, Zhang L, Gui Z, Cai X, Hu P, Wang J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Nature communications | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1038/s41467-025-67533-7'&gt;10.1038/s41467-025-67533-7&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-14&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41535264/'&gt;41535264&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Medullary thyroid carcinoma (MTC) is a rare, aggressive neuroendocrine tumor with limited treatment options and frequent recurrence. Comprehensive recurrence risk stratification remains lacking. Here, we profile 482 MTC samples from 452 patients across ten Chinese clinical centers, identifying 10,092 proteins and mutations in 87.0% of patients. Clinically, MTC grading, concurrent papillary thyroid carcinoma, and lymph node metastasis are significant recurrence risk factors, whereas at the genetic level, RET M918T and RET S891A mutations are correlated with high recurrence risk in sporadic and hereditary MTC, respectively. Ubiquitinomics show downregulated E3 ligases CUL4B and TRIM32 are associated with structural recurrence. We define three molecular subtypes with distinct outcomes and present an integrative machine learning model combining clinical, genomic, and proteomic features, validated in an independent test dataset of 105 patients and a published dataset. This multi-center, multi-omics study enhances the understanding of MTC heterogeneity and facilitates personalized patient management.</description>
    </item>
    <item>
      <title>#6 [75/100] Incorporation of grade into stage in oral cavity squamous cell carcinoma: A novel staging schema.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41534318/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41534318/</guid>
      <dc:creator>Ho AS, Luu M, Manzoor D, Maluf H, Bailey C, Balzer B, Walgama ES, Jang JK, Scher KC, Moyers JT, et al.</dc:creator>
      <pubDate>Tue, 13 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large dataset of nearly 47,000 cases and presents a novel staging schema that incorporates grade as a prognostic factor, which could have significant implications for clinical practice in oral cavity squamous cell carcinoma.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ho AS, Luu M, Manzoor D, Maluf H, Bailey C, Balzer B, Walgama ES, Jang JK, Scher KC, Moyers JT, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107847'&gt;10.1016/j.oraloncology.2025.107847&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-13&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41534318/'&gt;41534318&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: While numerous cancer staging systems have incorporated grade into stage, the impact of grade on oral cavity carcinoma (OCC) prognosis has been conflicting. We investigated grade as a prognostic determinant in OCC staging. METHODS: Multivariable Cox regression models of OCC patients identified via U.S. cancer registry data were constructed to determine associations between grade (G1¬†=¬†low-grade, G2¬†=¬†intermediate-grade, G3¬†=¬†high-grade) and overall survival (OS). Recursive partitioning analysis (RPA) was used to derive staging schema. RESULTS: Overall, 46,789 OCC cases were identified across 1,222 institutions. On univariate analysis, higher grade was associated with worse 5-yr OS (G1: 73% [95% CI 72-74%], G2: 61% [95 CI 60-61%], G3: 49% [95% CI 48-51%] (p¬†&lt;¬†0.001). On multivariable analysis adjusting for other prognostic factors, these survival differences persisted. Compared to G1 tumors, both G2 (HR 1.25 [95% CI 1.19-1.30], p¬†&lt;¬†0.001) and G3 (HR 1.52 [95% CI 1.45-1.61], p¬†&lt;¬†0.001) tumors were associated with significantly worse OS. Similar results were seen when utilizing propensity score matching. RPA generated subgroups that mirrored AJCC8E, but with G3 cases performing worse for a given stage. A proposed TNM¬†+¬†G staging schema was created with AJCC8E G3 cases upstaged by one category. Overall, 11.5% (4,745/36,623) cases were upstaged. TNM¬†+¬†G performed better than AJCC8E by c-index (0.673 vs. 0.671) and Brier score (0.174 vs. 0.175). CONCLUSION: Large-scale analysis supports grade as an influential predictive determinant in OCC outcomes, with hazard on par with conventional staging factors. Incorporation of grade into stage strengthens existing AJCC OCC schema and pragmatically improves its ability to convey prognosis.</description>
    </item>
    <item>
      <title>#7 [75/100] Dual-scale fusion vision transformer model for vocal cord leukoplakia risk stratification: A multicenter study.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41547298/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41547298/</guid>
      <dc:creator>Huang JL, Li LJ, Zhu JQ, Dou LZ, Liu YM, Ke Y, Zhao YD, Wang ML, Wang JH, Zhang QM, et al.</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter study utilizes a large dataset and advanced AI technology for risk stratification of vocal cord leukoplakia, which has significant clinical implications, although it is retrospective and not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang JL, Li LJ, Zhu JQ, Dou LZ, Liu YM, Ke Y, Zhao YD, Wang ML, Wang JH, Zhang QM, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; American journal of otolaryngology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.amjoto.2026.104789'&gt;10.1016/j.amjoto.2026.104789&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41547298/'&gt;41547298&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: This study aimed to develop an artificial intelligence (AI) system for accurate three-tier risk stratification of vocal cord leukoplakia (VCL), with particular focus on distinguishing high-risk lesions (severe dysplasia and carcinoma in situ) from low-risk and malignant lesions, while enhancing diagnostic performance among clinicians with limited experience. METHODS: This retrospective multicenter study analyzed 8510 laryngoscopic images from 743 patients across three tertiary hospitals in China. A dual-scale Vision Transformer (ViT) architecture was constructed, integrating multi-scale feature analysis with cross-attention fusion mechanisms. The model was rigorously evaluated through internal-external validation and a prospective reader study involving 12 endoscopists of varying expertise. RESULTS: The AI system demonstrated superior performance in three-tier classification, achieving F1-scores of 0.883 (95% CI: 0.869-0.896) and 0.861 (95% CI: 0.844-0.878) for high-risk lesion identification in internal and external validation, respectively. AI assistance significantly improved junior endoscopists' sensitivity from 67.1% to 81.4% (P¬†&lt;¬†0.001), effectively narrowing diagnostic performance disparities with senior experts. The system maintained robust generalizability across institutions, with 90.5% accuracy under heterogeneous imaging protocols. CONCLUSION: The proposed AI framework provides a clinically effective solution for reliable VCL risk stratification and reduces diagnostic variability between clinicians. Validated across multiple centers, this dual-scale ViT approach establishes a novel paradigm for laryngoscopic diagnosis and holds significant potential to standardize diagnostic workflows in resource-limited settings.</description>
    </item>
    <item>
      <title>#8 [75/100] Oncologic Outcomes of Transoral Robotic Surgery in HPV-Associated OPSCC: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41521853/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41521853/</guid>
      <dc:creator>Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG</dc:creator>
      <pubDate>Mon, 12 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies and a large patient cohort, providing important insights into oncologic outcomes of TORS in HPV-associated OPSCC, which could influence clinical practice.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Cheung MH, Kim CH, Nguyen SA, Williamson L, Kejner A, Bobian M, Newman JG&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ohn.70101'&gt;10.1002/ohn.70101&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-12&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41521853/'&gt;41521853&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To define survival and recurrence outcomes of HPV associated oropharyngeal squamous cell carcinoma (OPSCC) following transoral robotic surgery (TORS). DATA SOURCES: PubMed, Scopus, CINAHL. REVIEW METHODS: A systematic review and meta-analysis were performed on studies employing TORS in HPV-associated OPSCC. Meta-analysis of continuous measures, proportions, and comparison of weighted proportion and relative risk were performed for patient characteristics and outcomes. RESULTS: A total of 58 studies, comprising 16,129 adults treated with TORS for OPSCC, were included. The mean age was 59.5 years (SD 2.08) (range 18-93), with an average follow-up of 43.4 months (SD 13.36); 83.5% of the cohort was male, and 85.6% had HPV-positive OPSCC. In the HPV-positive group, TORS survival rates were 91.0% at 1 year, 94.9% at 3 years, and 89.8% at 5 years. In comparison, the HPV-negative group had survival rates of 92.3%, 84.2%, and 72.9%, respectively. Significant survival differences were observed between cohorts at 3 and 5 years (P‚Äâ&lt;‚Äâ.0001). The HPV-positive group had a significantly higher likelihood of 5-year overall survival compared to the HPV-negative group (RR‚Äâ=‚Äâ1.18, 95% CI: 1.05-1.34) Recurrence rates in HPV-positive patients were 2.0% local, 3.1% regional, and 5.3% locoregional, whereas HPV-negative patients had recurrence rates of 7.6% local, 6.0% regional, and 9.1% locoregional (P‚Äâ=‚Äâ.0037, .2143, .426, respectively). Distant metastasis rates were 5.6% in HPV-positive and 10.2% in HPV-negative patients (P‚Äâ=‚Äâ.0033). CONCLUSION: The higher survival rates and lower recurrences in HPV-positive OPSCC patients compared to their HPV-negative counterparts reflects the favorable long-term oncologic outcome seen in HPV-associated OPSCC.</description>
    </item>
    <item>
      <title>#9 [70/100] Comparative analysis of prevalences of sensorineural hearing loss from chemoradiotherapy versus radiotherapy in head and neck cancer patients: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41535758/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41535758/</guid>
      <dc:creator>Bukuru J, Sibomana O</dc:creator>
      <pubDate>Wed, 14 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important clinical question regarding the prevalence of sensorineural hearing loss in head and neck cancer patients treated with different modalities, providing valuable insights that could influence clinical practice, although it is based on existing literature rather than new data.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Bukuru J, Sibomana O&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-026-15551-z'&gt;10.1186/s12885-026-15551-z&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-14&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41535758/'&gt;41535758&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Head and neck cancer (HNC) is the seventh most prevalent cancer globally. Chemoradiotherapy (CRT) and radiotherapy (RT) are the two most common treatment modalities for HNC. However, both treatments are associated with adverse side effects, including hearing loss. This systematic review and meta-analysis aim to evaluate the pooled prevalence of sensorineural hearing loss (SNHL) among HNC patients undergoing CRT versus RT. METHODOLOGY: A comprehensive search of PubMed/MEDLINE, Google Scholar, DOAJ, AJOL, and the Cochrane Library was conducted using predefined key terms to identify original articles reporting the prevalence of SNHL in HNC patients treated with CRT or RT. Additionally, manual Google searches were performed to uncover relevant grey literature. The results were screened and included or excluded according to preset criteria. The Restricted Maximum Likelihood (REML) random-effects model was employed to calculate the overall pooled prevalence and separate prevalences in CRT and RT groups, as well as their respective heterogeneities, using Jamovi 2.3.28 software. Statistical significance was set at p‚Äâ&lt;‚Äâ.05 for all analyses. RESULTS: The overall prevalence of SNHL among HNC patients treated with CRT or RT was 54.5% (95% CI: 44.9% -‚Äâ64.0%; I¬≤ = 90.35%, p‚Äâ&lt;‚Äâ.001). For CRT, the prevalence was 60.4% (95% CI: 50.5% -‚Äâ70.2%; I¬≤ = 88.82%, p‚Äâ&lt;‚Äâ.001). In contrast, the prevalence for RT was 32.9% (95% CI: 21.3% -‚Äâ44.4%; I¬≤ = 60.15%, p‚Äâ=‚Äâ.063). The risk of developing SNHL was nearly twice as high in patients treated with CRT compared to those treated with RT alone, with a prevalence ratio of 1.83. CONCLUSION: Both CRT and RT are associated with SNHL in HNC patients, with a significantly higher prevalence observed in those undergoing CRT compared to RT.</description>
    </item>
    <item>
      <title>#10 [65/100] Molecular Profiling and Real-World Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41543354/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41543354/</guid>
      <dc:creator>Chirra M, Elliott A, Shaikh H, McGrath J, El-Gamal D, Karnezis AN, Abdulla FR, Ikpeazu C, Leddon J, Sukari A, et al.</dc:creator>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study involves a large cohort (1348 patients) and provides important real-world insights into the outcomes of BRAF V600E-mutated papillary thyroid cancer, but it is retrospective and does not present randomized controlled trial data or definitive practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Chirra M, Elliott A, Shaikh H, McGrath J, El-Gamal D, Karnezis AN, Abdulla FR, Ikpeazu C, Leddon J, Sukari A, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-3932'&gt;10.1158/1078-0432.CCR-25-3932&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41543354/'&gt;41543354&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;INTRODUCTION: Radioactive iodine refractory papillary thyroid cancers (PTC) containing BRAF-V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared to tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF-mut and BRAF-wildtype (wt) PTC. METHODS: Thyroid tumor samples underwent DNA/RNA next-gen sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using QuanTIseq. Insurance claims data was used to infer real-world overall survival (OS) and time on treatment. RESULTS: A total of 1348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF-V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%), and more prevalent in BRAF-mut versus (vs) BRAF-wt. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-wt PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, p&lt;0.001) and had significantly higher IFNŒ≥ scores. OS was not significantly different between patients with BRAF-mut vs wt PTC. Systemic treatment (BRAF/MEKi, TKI or IO) was not associated with significant differences in OS in‚ÄØBRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared to BRAF/MEKi or IO. CONCLUSIONS: BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.</description>
    </item>
  </channel>
</rss>
